MET and non-small cell lung carcinoma: Genomic aberrations in the MET gene, in the form of amplifications or mutations, represent a shared off-target resistance mechanism across subsets of NSCLC including EGFR-mutated or ALK, ROS1, RET fusion-driven NSCLC.